Текст уведомления здесь

Russian scientists started to develop an affordable medication for cancer immunotherapy

Siberian scientists, supported by the Russian Foundation for Basic Research (RFBR), have started to develop an affordable medication for immunotherapy of oncological diseases; the mechanism of action of the medication would be based on the discoveries of the winners of Nobel Prize in Physiology or Medicine of 2018, said Dmitry Stetsenko, the head of a laboratory at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) of the Siberian Branch of the Russian Academy of Sciences.
Добавить в закладки
Комментарии

However, the cost of treatment with medications for immunotherapy of cancer based on monoclonal antibodies is very high, and one of the tasks of the Siberian scientists is to make the medication cheaper.

«The goal of our project is to develop an approach to the creation of anticancer medications that would be no less effective than monoclonal antibodies and yet more accessible to a wide range of cancer patients,» Stetsenko said in conclusion.

Stetsenko also noted that the subject of the project is directly related to the works of the Nobel laureates in Physiology or Medicine of 2018.

Добавить в закладки
Комментарии
Вам понравилась публикация?
Расскажите, что вы думаете, и мы подберем подходящие материалы